EXACT Therapeutics restarts Phase I ACTIVATE study
Restarting its Phase I study – EXACT-Tx successfully enrols first patient at the Royal Marsden Hospital in London, UK, following temporary suspension due to Covid-19.
OSLO/LONDON SEPTEMBER 03 2020: EXACT THERAPEUTICS AS (“ EXACT-Tx” or the “Company”), a clinical stage precision medicine company utilizing Acoustic Cluster Therapy (ACT®) across multiple therapeutic areas, today announced that the phase I ACTIVATE study evaluating ACT® in patients with metastatic colorectal cancer has successfully enrolled the first patient following temporary suspension due to the Covid-19 pandemic. To date 6 patients have now been enrolled in the study being led by Professor Udai Banerji at the Royal Marsden Hospital (RMH) in London.
ACTIVATE study details:
● The first in man ACTIVATE study is a phase I evaluation of the innovative platform technology, Acoustic Cluster Therapy (ACT®) in the treatment of patients with metastatic colorectal and pancreatic cancer.
● This study is assessing the safety, tolerability and preliminary efficacy of ACT® co-administered with standard of care chemotherapy in these patients.
● To date the study has enrolled 6 patients at RMH with Professor Udai Banerji as principal investigator.
● Additional centres in the UK and Norway are planned as the study progresses.
Comment
“We are delighted to restart enrolment in the ACTIVATE study and look forward to continuing the clinical evaluation of the ACT® platform in patients with metastatic colorectal cancer" said Udai Banerji, NIHR Professor of Molecular Cancer Pharmacology and Honorary Consultant in Medical Oncology, Royal Marsden Hospital.
EXACT Therapeutics CEO, Dr Rafiq Hasan further commented "We are very grateful to Professor Banerji and the entire team at the Royal Marsden Hospital for their commitment and dedication to the ACTIVATE study with the enrolment of the first patient following the suspension due to Covid-19. This important study will provide important insights regarding the safety, tolerability, pharmacokinetics and preliminary efficacy of ACT® in the cancer setting.".
About ACT®
ACT® is a proprietary formulation consisting of microbubbles and microdroplets that are activated through the application of ultrasound with the consequent increase in targeted delivery of a co-administered therapeutic agent.
ACT® is supported by a strong and broad preclinical package demonstrating therapeutic enhancement in multiple oncology models (pancreatic, breast, colon, prostate) as well as blood-brain barrier penetration.
Initial focus of the company is oncology, however the ACT® platform has potential across therapeutic areas (infectious diseases, CNS, immunotherapy) and product classes.
About EXACT
EXACT-Tx is a clinical stage Anglo-Norwegian biotech company developing a technology platform for targeted therapeutic enhancement – Acoustic Cluster Therapy (ACT®). ACT® sonoporation is a unique approach to ultrasound-mediated, targeted drug enhancement – with the potential to significantly amplify the clinical utility of a wide range of therapeutic agents across a multitude of indications including within oncology (chemotherapy, immunotherapy), infectious diseases, and neurological conditions.
For more information contact:
Dr Rafiq Hasan, CEO of EXACT-Therapeutics
Rafiq@exact-tx.com
Richard Hayhurst/Janet Joy
Tel +44 7711 821527